Drug Insights

Unveiling Clopidogrel: How to Search for it on Synapse

20 February 2024
2 min read

Clopidogrel Bisulfate, a medication trademarked as Plavix®, was approved by Bristol Myers Squibb in the US in 1997. Its mechanism of action is to inhibit P2Y12 receptors, which reduces platelet activation and aggregation. This subsequently decreases the risk of blood clots and their potentially fatal consequences. Clopidogrel is indicated for treating myocardial infarction, stroke, peripheral vascular disease, coronary artery disease, and cerebrovascular disease. With its role as an antiplatelet agent, Clopidogrel proves invaluable in preventing severe complications from blood clots such as heart attacks, strokes, and even death. The drug has shown efficacy in the management and prevention of cardiovascular events, making it an essential medication in modern medicine. Click on the image below to begin the exploration journey of Clopidogrel through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Adverum Biotech's Phase 2 LUNA Study Shows Promising Ixo-vec Results for Wet AMD
Latest Hotspot
3 min read
Adverum Biotech's Phase 2 LUNA Study Shows Promising Ixo-vec Results for Wet AMD
20 February 2024
Adverum Biotech Reports Encouraging Initial Results for Safety and Effectiveness in Phase 2 LUNA Study of Ixo-vec for Wet Age-Related Macular Degeneration Patients.
Read →
Decoding Tasurgratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GI
Decoding Tasurgratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GI
20 February 2024
Tasurgratinib (E7090) is an orally available selective inhibitor of FGFR 1–3, the recommended dose is 140 mg per day per the dose-escalation part of a first-in-human phase 1 study.
Read →
Hemab Therapeutics reveals promising early results for Glanzmann's Thrombasthenia drug, HMB-001, at 2024 EAHAD Congress
Latest Hotspot
3 min read
Hemab Therapeutics reveals promising early results for Glanzmann's Thrombasthenia drug, HMB-001, at 2024 EAHAD Congress
19 February 2024
At the EAHAD Congress in 2024, Hemab Therapeutics Unveils Encouraging Initial Findings for Their Drug, HMB-001, Targeting Glanzmann's Thrombasthenia.
Read →
Expert Tips for Searching Hydralazine on Synapse
Drug Insights
2 min read
Expert Tips for Searching Hydralazine on Synapse
19 February 2024
Hydralazine Hydrochloride, marketed under the trade name Dralzine®, is an antihypertensive medication that has been approved since 1952 for the treatment of hypertension.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.